Waters Co. (NYSE:WAT) has received a consensus recommendation of “Hold” from the nineteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $201.25.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Waters from a “sell” rating to a “hold” rating in a report on Thursday, August 23rd. Goldman Sachs Group cut Waters from a “neutral” rating to a “sell” rating and decreased their price target for the company from $185.00 to $180.00 in a report on Friday, November 30th. ValuEngine upgraded Waters from a “hold” rating to a “buy” rating in a report on Tuesday, November 27th. UBS Group assumed coverage on Waters in a report on Tuesday, October 9th. They issued a “neutral” rating and a $210.00 price target on the stock. Finally, Cleveland Research upgraded Waters from a “sell” rating to a “neutral” rating in a report on Thursday, October 11th.
Waters stock traded down $4.94 during mid-day trading on Monday, hitting $188.94. The stock had a trading volume of 576,774 shares, compared to its average volume of 517,882. The stock has a market cap of $14.69 billion, a price-to-earnings ratio of 25.23, a P/E/G ratio of 2.32 and a beta of 0.97. Waters has a 12 month low of $167.93 and a 12 month high of $220.20. The company has a quick ratio of 5.93, a current ratio of 6.63 and a debt-to-equity ratio of 0.61.
Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, October 23rd. The medical instruments supplier reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.90 by $0.02. The business had revenue of $578.02 million for the quarter, compared to analysts’ expectations of $587.43 million. Waters had a return on equity of 30.68% and a net margin of 2.32%. The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.77 earnings per share. As a group, sell-side analysts expect that Waters will post 8.05 EPS for the current year.
In related news, Director Christopher A. Kuebler sold 8,000 shares of Waters stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $199.67, for a total value of $1,597,360.00. Following the sale, the director now owns 18,911 shares of the company’s stock, valued at approximately $3,775,959.37. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Thomas P. Salice sold 3,500 shares of Waters stock in a transaction that occurred on Wednesday, October 31st. The shares were sold at an average price of $192.00, for a total value of $672,000.00. Following the completion of the sale, the director now directly owns 20,911 shares in the company, valued at approximately $4,014,912. The disclosure for this sale can be found here. Company insiders own 0.98% of the company’s stock.
A number of institutional investors have recently made changes to their positions in WAT. Alps Advisors Inc. bought a new position in shares of Waters during the 2nd quarter worth approximately $478,000. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Waters by 5.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 7,118 shares of the medical instruments supplier’s stock worth $1,378,000 after acquiring an additional 391 shares during the period. TD Asset Management Inc. boosted its stake in shares of Waters by 74.0% during the 2nd quarter. TD Asset Management Inc. now owns 43,526 shares of the medical instruments supplier’s stock worth $8,427,000 after acquiring an additional 18,509 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Waters by 5.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 244,477 shares of the medical instruments supplier’s stock worth $47,328,000 after acquiring an additional 12,497 shares during the period. Finally, Smith Asset Management Group LP boosted its stake in Waters by 18.2% in the 2nd quarter. Smith Asset Management Group LP now owns 164,388 shares of the medical instruments supplier’s stock valued at $31,864,000 after purchasing an additional 25,303 shares during the period. 98.51% of the stock is currently owned by institutional investors and hedge funds.
Waters Company Profile
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Read More: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.